UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24 weeks of treatment
Keywords: اعتقاد; Metabolic disorders; Fatty acid oxidation disorders; Triheptanoin; UX007; FAOD; LC-FAOD; VLCAD; LCHAD;